Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail targets Hard-to-Treat lymphoma

NCT ID NCT05283720

Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study tests an experimental drug called epcoritamab given together with other anti-cancer medicines in adults with Non-Hodgkin lymphoma (NHL), a type of blood cancer. About 496 participants will receive different combinations depending on their lymphoma subtype and treatment history. The main goal is to check safety and how well the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Epcoritamab (an investigational antibody) combined with other anti-cancer drugs
What this could lead to
If successful, this could offer new combination treatment options for people with certain types of Non-Hodgkin lymphoma that are hard to treat.
What could go wrong
This is an early-phase trial (Phase 1b/2) testing many different drug combinations, so results may not lead to a standard treatment. Side effects from combining multiple anti-cancer drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

264 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Nov 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of: \-- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report: * DLBCL, not otherwise specified (NOS). * High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOS or other double- /triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible. * Follicular lymphoma (FL) Grade 3B. OR * FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy, according to WHO 2016 classification. OR * Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at most recent representative tumor biopsy according to the WHO 2016 classification with evidence of overexpression of cyclin D1 in association with relevant markers or evidence of t(11;14) assessed by flow cytometry, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR). * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arm 6A where ECOG performance status must be 0-1. * Must have 1 or more measurable disease sites: * A positron emission tomography (PET) /computed tomography (CT) scan demonstrating PET-positive lesion(s) AND * At least 1 measurable nodal lesion (long axis \> 1.5 cm) or \>= 1 measurable extra-nodal lesion (long axis \> 1.0 cm) on CT scan or magnetic resonance imaging (MRI). Exclusion Criteria: * Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20. * Toxicities from prior anticancer therapy that have not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with the exception of alopecia. Other eligibility criteria (e.g., laboratory, cardiac criteria) must also be met.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma hairy cell leukemia mantle cell lymphoma neoplasm non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma

Contacts and locations

Locations

  • Aalborg University Hospital /ID# 242734

    Aalborg, North Denmark, 9000, Denmark

  • Aarhus Universitetshospital - Skejby /ID# 242670

    Aarhus, Central Jutland, 8200, Denmark

  • Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144

    Kansas City, Missouri, 64114-4859, United States

  • Asan Medical Center /ID# 242400

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • Beijing Cancer Hospital /ID# 252303

    Beijing, Beijing Municipality, 100142, China

  • CHRU Lille - Hopital Claude Huriez /ID# 242335

    Lille, Nord, 59037, France

  • CHU Clermont-Ferrand /ID# 242344

    Clermont, Auvergne-Rhône-Alpes, 63100, France

  • CHU de Rennes - PONTCHAILLOU /ID# 242339

    Rennes, Brittany Region, 35000, France

  • CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 243268

    Madrid, 28027, Spain

  • Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 242342

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54511, France

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 242345

    Nantes, Pays de la Loire Region, 44000, France

  • China Medical University Hospital /ID# 242893

    Taichung, 40447, Taiwan

  • Christiana Care Health Service /ID# 242301

    Newark, Delaware, 19713, United States

  • Clinica Universidad de Navarra - Pamplona /ID# 245031

    Pamplona, Navarre, 31008, Spain

  • Debreceni Egyetem-Klinikai Kozpont /ID# 242450

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Duplicate_Erasmus Medisch Centrum /ID# 243315

    Rotterdam, South Holland, 3015 GD, Netherlands

  • East Carolina University - Brody School of Medicine /ID# 242506

    Greenville, North Carolina, 27834, United States

  • Fakultni Nemocnice Brno - Jihlavska /ID# 242683

    Brno, Brno-mesto, 625 00, Czechia

  • Fakultni Nemocnice Ostrava /ID# 242684

    Ostrava, Ostrava-mesto, 708 52, Czechia

  • Fakultni nemocnice Hradec Kralove - Sokolska /ID# 241722

    Hradec Králové, 500 05, Czechia

  • Fox Chase Cancer Center /ID# 242106

    Philadelphia, Pennsylvania, 19111, United States

  • Fudan University Shanghai Cancer Center /ID# 252292

    Shanghai, Shanghai Municipality, 200032, China

  • HCL - Hopital Lyon Sud /ID# 242349

    Pierre-Bénite, Rhone, 69495, France

  • Hadassah Medical Center-Hebrew University /ID# 243013

    Jerusalem, Jerusalem, 91120, Israel

  • Hokkaido University Hospital /ID# 248999

    Sapporo, Hokkaido, 060-8648, Japan

  • Hopital Pitie Salpetriere /ID# 242343

    Paris, Île-de-France Region, 75013, France

  • Hopital Saint-Louis /ID# 242336

    Paris, 75010, France

  • Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 242337

    Créteil, Paris, 94010, France

  • Hospital Clinico Universitario de Valencia /ID# 243269

    Valencia, 46010, Spain

  • Hospital Universitario 12 de Octubre /ID# 243262

    Madrid, 28041, Spain

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 243264

    Madrid, 28040, Spain

  • Hospital Universitario Vall de Hebron /ID# 243260

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen del Rocio /ID# 243267

    Seville, 41013, Spain

  • Hospital Universitario de Salamanca /ID# 243368

    Salamanca, 37711, Spain

  • IUCT Oncopole /ID# 242340

    Toulouse, Occitanie, 31059, France

  • Icahn School of Medicine at Mount Sinai /ID# 242123

    New York, New York, 10029, United States

  • Institut Catala dOncologia - LHospitalet /ID# 243261

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Instituto Catalan de Oncologia (ICO) Badalona /ID# 243265

    Badalona, Barcelona, 08916, Spain

  • Joe Arrington Cancer Research /ID# 242226

    Lubbock, Texas, 79410, United States

  • Klinikum Augsburg /ID# 244523

    Augsburg, Bavaria, 86156, Germany

  • Kyoto University Hospital /ID# 248997

    Kyoto, Kyoto, 606-8507, Japan

  • Leids Universitair Medisch Centrum /ID# 243316

    Leiden, South Holland, 2333 ZA, Netherlands

  • Maastricht Universitair Medisch Centrum /ID# 243317

    Maastricht, Limburg, 6229 HX, Netherlands

  • MultiCare Institute for Research and Innovation /ID# 242127

    Tacoma, Washington, 98405, United States

  • National Cancer Center Hospital /ID# 248995

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cheng Kung University Hospital /ID# 242894

    Tainan, 704, Taiwan

  • Northwell Health - Monter Cancer Center /ID# 245435

    Lake Success, New York, 11042, United States

  • Novant Health Forsyth Medical Center /ID# 242198

    Winston-Salem, North Carolina, 27103, United States

  • Novant Health Presbyterian Medical Center /ID# 242148

    Charlotte, North Carolina, 28204, United States

  • Orszagos Onkologiai Intezet /ID# 242458

    Budapest, 1122, Hungary

  • Rabin Medical Center. /ID# 243014

    Petah Tikva, Central District, 4941492, Israel

  • Samsung Medical Center /ID# 242401

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Semmelweis Egyetem /ID# 242454

    Budapest, 1085, Hungary

  • Seoul National University Bundang Hospital /ID# 242404

    Seongnam-si, Gyeonggido, 13620, South Korea

  • Seoul National University Hospital /ID# 242402

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 245935

    Kaposvár, Somogy County, 7400, Hungary

  • Swedish Medical Center - Seattle /ID# 242269

    Seattle, Washington, 98104, United States

  • Taipei Veterans General Hosp /ID# 242892

    Taipei, 11217, Taiwan

  • Tampa General Hospital /ID# 246748

    Tampa, Florida, 33606, United States

  • Tel Aviv Sourasky Medical Center /ID# 243012

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242403

    Seoul, Seoul Teugbyeolsi, 06591, South Korea

  • The Chaim Sheba Medical Center /ID# 243010

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The University of Arizona Cancer Center - North Campus /ID# 242219

    Tucson, Arizona, 85719, United States

  • Thomas Jefferson University Hospital /ID# 242077

    Philadelphia, Pennsylvania, 19107, United States

  • Thompson Cancer Survival Ctr /ID# 242150

    Knoxville, Tennessee, 37916, United States

  • Universitaetsklinikum Giessen und Marburg /ID# 245308

    Marburg, Hesse, 35043, Germany

  • Universitaetsklinikum Leipzig /ID# 245513

    Leipzig, Saxony, 04103, Germany

  • Universitaetsklinikum Regensburg /ID# 244517

    Regensburg, Bavaria, 93042, Germany

  • Universitaetsklinikum Ulm /ID# 244265

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitaetsklinikum Wuerzburg /ID# 245453

    Würzburg, Bavaria, 97080, Germany

  • Universitair Medisch Centrum Groningen /ID# 243318

    Groningen, 9713 GZ, Netherlands

  • University of Maryland, Baltimore /ID# 242218

    Baltimore, Maryland, 21201, United States

  • Vrije Universiteit Medisch Centrum /ID# 243319

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Vseobecna Fakultni nemocnice v Praze /ID# 242685

    Prague, Praha 17, 128 00, Czechia

  • Winship Cancer Institute of Emory University /ID# 242153

    Atlanta, Georgia, 30322, United States

  • Yale University School of Medicine /ID# 242089

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.